What is the difference between a biostimulator and a traditional filler?

HA (hyaluronic acid) fillers provide immediate volume by drawing water into the injection site. They are reversible with hyaluronidase enzyme and typically last 6 to 18 months. Biostimulators like Sculptra and Radiesse stimulate the body's own collagen and elastin production. Results are gradual, appearing over 2 to 3 months, but can last 2 years or more. The goal is structural improvement, not immediate volume.

How are Sculptra and Radiesse different?

Sculptra contains PLLA (poly-L-lactic acid) microspheres that slowly degrade and stimulate deep collagen production over 2 to 3 months, with effects lasting up to 2 years. Radiesse contains CaHA (calcium hydroxyapatite) and provides immediate volume alongside collagen stimulation, with effects lasting 12 to 18 months. Both are FDA-approved. Sculptra requires a series of sessions; Radiesse may show results sooner.

Are polynucleotides considered biostimulators?

Yes. Polynucleotides (PN) and PDRN are extracted from salmon or trout DNA and work by promoting tissue regeneration and collagen synthesis through growth factor receptor stimulation. They are widely used in Europe and Asia, focus on skin texture and density rather than volume, and are categorized as biostimulators because they trigger endogenous collagen production rather than filling space directly.

Biostimulatory Fillers: The Next Generation That Builds Collagen, Not Just Volume

Two frustrations drive change in the filler market. The first is the look: too much volume, too quickly, in ways that read as done rather than rested. The second is the timeline: six months later, back in the chair. Biostimulatory fillers address both by asking a different question. Instead of what can we put into the skin, the question becomes what can we get the skin to make.

A Market at an Inflection Point

The global HA filler market was valued at $5.26 billion in 2025 and is projected to reach $15.35 billion by 2035 (CAGR 11.3%). Cross-linked HA still holds 63 percent market share, anchored by its reversibility and immediate visible results.

But patient priorities are shifting. A 2025 survey of aesthetic treatment patients found that 59 percent cited longevity of results as their primary consideration. That preference gap between what HA fillers offer and what patients want is where biostimulators are positioned.

How Biostimulators Work

Traditional HA fillers create volume through fluid displacement. Hyaluronic acid molecules attract water molecules at a roughly 1:1000 ratio, inflating the injection zone. The effect is immediate and visible. The limitation is that it is borrowed volume, maintained as long as the HA persists, and gone when it degrades.

Biostimulators work through cellular signaling. The injected material acts as a scaffold or chemical signal that prompts fibroblasts to produce collagen and elastin. No borrowed volume; the tissue builds its own structural support.

Sculptra (PLLA): Poly-L-lactic acid microspheres are injected into deep tissue layers. The particles degrade slowly over several months, and the degradation process triggers a controlled inflammatory response that stimulates fibroblast activity. Collagen production builds gradually, with visible improvement typically appearing 2 to 3 months post-injection and lasting up to 2 years. FDA-approved since 2004 for facial lipoatrophy and since 2009 for cosmetic correction of facial wrinkles.

Radiesse (CaHA): Calcium hydroxyapatite microspheres suspended in gel. The gel component provides immediate volume; the microspheres stimulate collagen as they degrade. Radiesse offers a hybrid approach: faster initial results than Sculptra with biostimulatory benefits. Duration is approximately 12 to 18 months.

Polynucleotides (PN/PDRN): Derived from salmon or trout DNA. They bind to adenosine receptors and stimulate growth factors that drive tissue regeneration and collagen synthesis. Widely used in Korea, Italy, and across Europe, they are gaining traction in the US market. The focus is skin quality improvement: texture, hydration, firmness, and density, rather than volume restoration.

The Natural-Looking Shift in 2026

The aesthetic treatment trend in 2026 is moving toward outcomes that are undetectable rather than visible. The language in clinical practice has shifted from adding volume to restoring structural integrity. Biostimulators fit this framing because the result is the patient’s own collagen, built gradually, looking like an improvement in skin health rather than an intervention.

This has created a two-category market dynamic: HA for immediate, targeted volume correction; biostimulators for foundational improvement in skin structure over time. Many practices now combine both in sequenced protocols.

Clinical Considerations

Biostimulators are not reversible in the way HA fillers are. There is no equivalent of hyaluronidase to dissolve Sculptra or Radiesse if placement is suboptimal. Managing patient expectations about the gradual timeline is essential, particularly for patients accustomed to instant HA results.

PLLA can form nodules if injection technique, product dilution, or post-treatment massage protocol is incorrect. CaHA should not be injected superficially. Polynucleotide injection depths and concentrations vary by formulation.

The clinical skill requirement is higher than for standard HA filler injection. Provider selection, specifically a practitioner with documented experience with the specific biostimulator being used, is the most important variable in outcome and safety.

Source: La Belle Vie / Mountcastle Med Spa